Mechanism of Action Trial of ColoAd1 — MOA

Resectable Non-small Cell Lung Cancer Clinical Trial

Official title:
A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour

Status Completed

Clinical Trial Summary

To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02053220
Study type	Interventional
Source	PsiOxus Therapeutics Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	June 2013
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06169956` - An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
Recruiting	`NCT05472623` - Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab	Phase 2
Recruiting	`NCT06161441` - A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery	Phase 2
Not yet recruiting	`NCT05247684` - AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC	Phase 2